Neuropathix, Inc. (NPTX)
| Market Cap | 18.76K |
| Revenue (ttm) | 359,457 |
| Net Income (ttm) | -3.82M |
| Shares Out | 93.81M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,500 |
| Open | 0.0004 |
| Previous Close | 0.0004 |
| Day's Range | 0.0004 - 0.0004 |
| 52-Week Range | 0.0002 - 0.0479 |
| Beta | 1.55 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About NPTX
Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary synthetic cannabinoid derivatives platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopath... [Read more]
Financial Performance
Financial StatementsNews
Neuropathix, Inc. Highlights Revenue Related to its Grant Award with NIH-NINDS
The three-year $2.97 million Phase 2 STTR Study Grant through the NIH HEAL Initiative (Helping End Addiction Long-term) is providing funding specifically in the Development of KLS-13019 for Neuropathi...
Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019
Published Preclinical Data Shows KLS-13019 More Effective Than Cannabidiol (CBD) in Prevention, Reversal of Chemotherapy-Induced Peripheral Neuropathy (CIPN) DOYLESTOWN, PA / ACCESSWIRE / April 13, 20...
Neuropathix, Inc. CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding
DOYLESTOWN, PA / ACCESSWIRE / April 6, 2022 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today that its CE...
Neuropathix, Inc. Welcomes Daniele Piomelli, PhD, MD to the Company's Scientific Advisory Board
DOYLESTOWN, PA / ACCESSWIRE / January 25, 2022 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announces today that it ...
Neuropathix, Inc. Receives Patent Grant from India for Its Novel Anti-Inflammatory Compounds
DOYLESTOWN, PA / ACCESSWIRE / January 18, 2022 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, today announces that the...
Neuropathix, Inc. Chooses Purisys for Process Optimization and Scale Up of Its Lead Drug Candidate KLS-13019
DOYLESTOWN, PA / ACCESSWIRE / November 17, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible life sciences company focused on the research and development ...
Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)
Pharmaceutical Assets Include Company's Non-Opioid Anti-inflammatory Compound KLS-13019 to Treat Chemotherapy Induced Peripheral Neuropathy (CIPN) Company's Strategy is to Utilize the Phase 2 Study Gr...
Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company's Over-The-Counter Cosmeceutical Assets
Cosmeceutical Assets Include Company's Lead Anti-inflammatory OTC Cosmeceutical Compound called LEA™ (Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine) Company's Strategy is to Enable Dermique to Foc...
Neuropathix, Inc. Appoints Michael Ropacki, PhD to the Company's Scientific Advisory Board
DOYLESTOWN, PA / ACCESSWIRE / August 12, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announces today that it h...
Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders
DOYLESTOWN, PA / ACCESSWIRE / July 20, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today the publica...
Neuropathix, Inc. Announces Publication of Validated Preclinical Studies on KLS-13019 in the British Journal of Pharmacology
DOYLESTOWN, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today the pu...
Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead
DOYLESTOWN, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today that ...
Neuropathix, Inc. Announces Publication of Its Global PCT Patent for NPTX-204, a Novel Hops-Inspired Neuroprotectant
DOYLESTOWN, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced the publica...
Neuropathix, Inc. Acquires Neuroprotective and Anticonvulsant Intellectual Property Estate
DOYLESTOWN, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (OTCQB: NPTX), (the “Company” or "Neuropathix"), a socially responsible pain management life sciences company, announced today that...